Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.00 -0.22% 898.00 890.00 910.00 910.00 900.00 900.00 171,694 16:35:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16.3 -9.7 -17.3 - 667

Maxcyte Share Discussion Threads

Showing 726 to 749 of 750 messages
Chat Pages: 30  29  28  27  26  25  24  23  22  21  20  19  Older
DateSubjectAuthorDiscuss
15/6/2021
10:41
I make that 8 NEDs now!!
trident5
14/6/2021
20:19
Interesting article behind paywall Biotech firm MaxCyte signs lease for new headquarters in Montgomery County "...inked a 67,000-square-foot lease, taking more than half of a five-story building." "...secured a long term, below market lease to boost their growth trajectory." "...plans to "substantially increase its workforce" in the new space" stated the agent for the company. hTTps://www.bizjournals.com/washington/news/2021/06/14/pharma-company-moving-hq-in-rockville.html
pob69
11/6/2021
11:01
This data is v good hTTps://investors.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-present-new-data-22-patients Vertex Pharmaceuticals (NASDAQ:VRTX) and CRISPR Therapeutics (NASDAQ:CRSP) announce new data on 22 patients, with follow-up of at least 3 months, treated with CRISPR/Cas9-based gene-editing therapy, CTX001. Beta thalassemia: All 15 patients were transfusion independent after CTX001 infusion and had clinically meaningful improvements in total hemoglobin from 8.9 to 16.9 g/dL and fetal hemoglobin from 67.3% to 99.6% at last visit. Sickle cell disease: All seven patients were free of vaso-occlusive crises after CTX001 infusion and had meaningful improvements in total hemoglobin from 11 to 15.9 g/dL and fetal hemoglobin levels from 39.6% to 49.6% at last visit. The safety data from all 22 patients were generally consistent with an autologous stem cell transplant and myeloablative conditioning. Bone marrow allelic editing data collected from patients who have at least six months of follow-up, demonstrated a durable effect.
nimbo1
04/6/2021
13:40
Good clear starter presentation from 55mins: htTps://www.youtube.com/watch?v=Uua6DCTnZvU
rambutan2
03/6/2021
14:44
Yes I think that most of us would have realised that. Not our resident cup half empty tho, of course....
assagai
03/6/2021
14:01
Just to clarify when I wrote "I was on the MaxCyte board" I meant I was reading this investment board NOT I was on the board of directors for MaxCyte, I have no connection other than as a potential investor. Apologies for any genuine confusion caused. Best regards SBP
stupidboypike
03/6/2021
12:49
Time gentlemen please....
assagai
03/6/2021
12:30
"I was on the MaxCyte board..." Really, tell us more, spill the beans. Were you pushed or did you walk out?
trident5
03/6/2021
12:06
A while ago someone asked here if anyone knew any other "Picks and shovels" businesses in the bio space. At the time Arecor, which I believe does fit that description, was a private company. However, this morning it had an IPO and floated on the AIM market. In a nutshell, Arecor improve existing medicines giving them various improved characteristics by adding excipients and have strong patent protection for their techniques. One of the big advantages is that there is often a much reduced path to regulatory approval in comparison to an entirely new drug. Their two lead products show improved speed of onset and improved concentration for insulin. I was on the MaxCyte board as it was mentioned to me as a comparable to Arecor (obviously a few years further forward). Please DYOR, and apologies to anyone not interested :- https://uk.advfn.com/cmn/fbb/thread.php3?id=48471274 Best regards SBP
stupidboypike
02/6/2021
08:47
New presentation by Sarah Meeks, Ph.D., VP of Business Development hTTps://www.youtube.com/watch?v=ZMUbfwfc5vU
pob69
27/5/2021
08:30
Interesting article hTTps://www.nanalyze.com/2021/05/maxcyte-stock-investing-cell-therapy/
pob69
25/5/2021
13:26
Maybe it's only apparently being marked down?
trident5
25/5/2021
13:00
Don't think I've ever seen maxcyte marked down on a positive news day , very unusual. Especially as a lot of the early morning apparent sells were in fact buys.
assagai
25/5/2021
10:58
wouldn't surprise me at all if its around here, SEC has a bit of a backlog for new IPO requests at the moment
nimbo1
25/5/2021
10:23
STNO seem to be wanting to keep a lid on here @9.10...float price equivalent??
assagai
21/5/2021
10:29
Editas CMO Lisa Michaels, on delivery in gene editing: "The next stages of development in this area are probably going to move away from viral vectors."
nimbo1
20/5/2021
09:30
This potentially could be an important breakthrough longer term for key Maxyte partner “...We are delighted to present updated data on what we believe to be the most advanced allogeneic CAR T program in development. Longer-term data from the ALPHA trial of ALLO-501 in combination with ALLO-647 demonstrate for the first time the ability of an off-the-shelf cell therapy to induce durable responses in NHL patients similar to that seen in trials of autologous therapies,” said Rafael Amado, M.D., Executive Vice President of Research and Development and Chief Medical Officer at Allogene. hTTps://www.globenewswire.com/news-release/2021/05/19/2232864/0/en/Allogene-Therapeutics-CD19-Forum-Highlights-Positive-Results-from-Phase-1-Studies-of-ALLO-501-and-ALLO-501A-in-Relapsed-Refractory-Non-Hodgkin-Lymphoma-and-Plan-to-Initiate-Pivotal.html
pob69
14/5/2021
13:50
Judging by the sponsors and the people doing the voting, I wouldn't place any emphasis on a MediScience award. There are loads of these types of "awards" that are voted on by the media, financial PR and broker community. The awards are normally put on by an event company (eg "Ford Sinclair is a family-run event management company, with over 30 years' experience in delivering high profile live events"). The purpose of the "event" is to sell >£1,000 tables to the attendees. The shortlist is normally determined by the award sponsor and might well be focused on target or existing clients. The awards (particularly company of the year) often go to the companies and executives whose share prices increased the most in the recent past. I would be very surprised if the company submitted anything. But, the company (and its advisors) will now be contacted incessantly to encourage attendance at the event in November to eat rubbery chicken, drink overpriced wine, listen to 15 mins of a comedian du jour and, possibly, collect an award. It would be interesting to know if companies that don't pay to attend ever receive awards.
gsbmba99
14/5/2021
11:52
I think Trident has a fair point. I doubt games workshop, a retail presence selling to the consumer market would get much value out of awards or nominations given your average Warhammer model purchaser is not likely swayed away from DnD to Middle Earth by these awards. That would be fairly typical of that type of B2C company. In the B2B world however, there are rarely cheaper or more effective ways to raise awareness or to give a level of comfort to the potential purchaser than a consistent presence across a range of channels. In the non virtual world there are also excellent networking opportunities, although presently that is not likely to be a fruitful online. Also the people who make their income from these events utilise judges from within the industry in order to give credibility. The judges themselves are doing it to raise their own awareness so they have a lot to lose by choosing a dud one. It rather shows their lack of awareness or acumen. So personally, I think the recognition has some validity. A successful business it does not make of course. But a negative? I don't believe so.
eaglebeagle
14/5/2021
11:50
I agree with trident's principle - basking in glory is not something a shareholder wants to see - however these are just nominations and actually its a good thing for exposure in the industry I would think. Whereas GAW would have 0 benefit from it as their customers don't give a monkeys (I've enjoyed being a GAW shareholder in the past). Nice to see nasdaq listing process moving ahead - market conditions are certainly ropy at the mo - one goes from hoping the price will double to hoping the price will stay steady : )
nimbo1
14/5/2021
11:12
No need to apologise, it rather amused me. I’d argue that at this stage in Maxcyte life, being nominated for these awards is a good way to promote awareness of the company. Not sure how much time is taken up in current climate. Maybe no more than opening up an email and 20mins on a virtual award ceremony.
acuere
14/5/2021
10:44
It was just an observation about the way a Board thought at a hugely successful company. My apologies if it spoilt your morning. Where I used to work we stopped competing for industry awards because of the time sucked up by submissions and attendance. The same organisations competed each year, not because they were the best, but because they were over-staffed in HO.
trident5
14/5/2021
10:24
trident still sucking the joy out of life I see!! Anyway, after yesterday’s tidying up announcement, first stage to Nasdaq listing commences. To try and gage a timeline I was looking at some of Synconas recent Nasdaq IPOs. Autolus - initial registration early March 2018. Floated late June 2018. Freeline - registration announced 20 July 2020. Floated 7th August. But on the downside. Gyroscope - registration announced 19 April 2021. IPO ditched due to market conditions 7th May. Let’s hope the markets stabilise.
acuere
14/5/2021
10:13
C.mon lads, drink up...
assagai
Chat Pages: 30  29  28  27  26  25  24  23  22  21  20  19  Older
ADVFN Advertorial
Your Recent History
LSE
MXCT
Maxcyte
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210622 20:44:12